Idk calprotectin elisa kit

Fecal samples were collected from melanoma patients before ICI treatment commenced and from healthy subjects. All participants received oral and written instructions regarding the stool-collection procedure (according to the modified protocol described by Dore et al. (2015) [11 ]). Briefly, they were requested to collect ~30 g of feces into provided fecal containers, preferably on the day of the scheduled hospital visit, and then store the samples at room temperature or 2–8 °C until they arrived at the hospital. The stool samples were delivered to the laboratory at room temperature, and 1 g of each stool sample was placed into a tube with RNAlater and incubated for 1 h at room temperature. Afterward, RNAlater-preserved feces were homogenized and centrifuged at 10,500 RPM for 3 min, and then the supernatant was thoroughly removed. Approximately 250 mg of fecal slurry was aliquoted into tubes and frozen at −20 °C until metagenomic DNA extraction.
Additionally, 15 mg of raw fecal samples was collected, and calprotectin concentration in stool was measured with IDK Calprotectin ELISA Kit (Immundiagnostik AG, Bensheim, Germany), according with the instructions of the kit manual.

The level of fecal calprotectin was quantified using the IDK Calprotectin ELISA Kit (Immundiagnostik AG, Germany) in accordance with the manufacturer’s instructions. Absorbance was read at a wavelength of 450 nm using a Synergy HT Multi-Detection Microtiter Plate Reader (BioTek, Winooski, VT). The samples were plated in duplicate and the assay was performed twice.

IFX and ADL trough levels were quantified using the enzyme-linked immunosorbent assay (IDKmonitor^® Infliximab Drug Level ELISA and IDKmonitor^® Adalimumab Drug Level ELISA kits; Immundiagnostik AG, Bensheim, Germany) during routine diagnostics. The timing of the evaluation was clinically decided. In most of the samples, IFX-ADA and ADL-ADA levels (554 of 730, 76%) were determined using the drug-tolerant enzyme-linked immunosorbent assay (IDKmonitor^® Infliximab total ADA ELISA and IDKmonitor^® Adalimumab total ADA ELISA kits; Immundiagnostik AG, Bensheim, Germany), which can detect free as well as drug-bound antibodies. In remaining samples (176 of 730, 24%), ADA levels were measured using the drug-sensitive enzyme-linked immunosorbent assay (IDKmonitor^® Infliximab free ADA ELISA and IDKmonitor^® Adalimumab free ADA ELISA kits; Immundiagnostik AG, Bensheim, Germany), which can detect free ADA.
Fecal calprotectin level was measured using the enzyme-linked immunoassay (IDK^® Calprotectin ELISA kit; Immundiagnostik AG, Bensheim, Germany). The routine measurement of C-reactive protein (CRP) levels was performed using the turbidimetric latex immunoassay on the ARCHITECT system (MULTIGENT CRP Vario, Abbott GmbH, Wiesbaden, Germany) from January 2013 until May 2020 and on the Cobas^® system (Tina-quant C-Reactive Protein IV, Roche Diagnostics GmbH, Mannheim, Germany) from June 2020 onwards.